PET and PET/CT in Kidney Cancer
Renal cell carcinoma comprises about 3% of all malignancies. FDG has a modest affinity for RCC related to a lower expression of GLUT-1 than other cancers. Metabolic imaging using FDG and PET has a modest accuracy for primary lesions and local recurrence. The data for staging and restaging of RCC is similar: low sensitivity and high specificity. Possible interpretation problems related to the excreted FDG can be overcome by fusion of anatomic and metabolic images (PET/CT). Newer-generation scanners have improved spatial resolution, which will reduce false negatives. To date, there are no series available about the utility of this emerging dual-modality imaging technique in RCC. The modality is also suitable for therapy monitoring, but again there is insufficient data to assess the contribution of PET or PET/CT.
KeywordsRenal Cell Carcinoma Standardize Uptake Value Brown Adipose Tissue Renal Cell Cancer Kidney Cancer
Unable to display preview. Download preview PDF.
- Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS (1999) Multi-center, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521–2529PubMedGoogle Scholar
- Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J, Phelps ME (1997) PET in oncology: Will it replace the other modalities? Semin Nucl Med 272:94–106Google Scholar
- Kocher F, Grimmel S, Hautmann R (1994) Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results. J Nucl Med 35: 223PGoogle Scholar
- Kubota K, Ishiwata K, Kubota R, Yamada S, Tada M, Sato T, Ido T (1991) Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [ 6-3H]thymidine, and gallium-67. J Nucl Med 32:2118–2123PubMedGoogle Scholar
- Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S (2002) Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohisto-chemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 9:15–18PubMedCrossRefGoogle Scholar
- Miyauchi T, Brown R, Grossman H, Wojno K (1996) Correlation between visualization of primary renal cancer by FDG-PET. J Nucl Med 37 (Suppl):64PGoogle Scholar
- Montravers F, Grahek D, Kerrou K, Younsi N, Beco V de, Talbot JN (2002) Sensitivity of FDG CDET (2D dual-head coincidence gamma camera) for the detection of occult or doubtful recurrences of colorectal cancer. Histopathological correlation. Clin Positron Imaging 3:169Google Scholar
- Phelps ME (ed) (2004) PET: molecular imaging and its biological applications. Springer, Berlin Heidelberg New YorkGoogle Scholar
- Valk P (ed) (2003) Positron emission tomography: basic science and clinical practice. Springer, Berlin Heidelberg New YorkGoogle Scholar
- Warburg O, Posener K, Negelein E (1924) The metabolism of cancer cells. Biochem Zeitschr 152:129–169Google Scholar